The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin
Open accessAbstract
The plasminogen (Plg)/plasminogen activator (PA) system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumor cell migration. Consequently, urokinase-type PA (uPA)/plasmin antagonists are currently being developed for suppression of tumor growth and angiogenesis. Paradoxically, however, high levels of PA inhibitor 1 (PAI-1) are predictive of a poor prognosis for survival of patients with cancer. We demonstrated previously that PAI-1 promoted tumor angiogenesis, but by an unresolved mechanism. We anticipated that PAI-1 facilitated endothelial cell migration via its known interaction with vitronectin (VN) and integrins. However, using adenoviral gene transfer of PAI-1 mutants, we observed that PAI-1 promoted tumor angiogenesis, not by interacting with VN, but rather by inhibiting proteolytic activity, suggesting that excessive plasmin proteolysis prevents assembly of tumor vessels. Single deficiency of uPA, tissue-type PA (tPA), uPA receptor, or VN, as well as combined deficiencies of uPA and tPA did not impair tumor angiogenesis, whereas lack of Plg reduced it. Overall, these data indicate that plasmin proteolysis, even though essential, must be tightly controlled during tumor angiogenesis, probably to allow vessel stabilization and maturation. These data provide insights into the clinical paradox whereby PAI-1 promotes tumor progression and warrant against the uncontrolled use of uPA/plasmin antagonists as tumor angiogenesis inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z · Cited by 1,546
Physiological consequences of loss of plasminogen activator gene function in mice
Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D., & Mulligan, R. C. (1994) · Nature · doi:10.1038/368419a0 · Cited by 1,037
Self-citationAbsence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677
Self-citationThe serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
Stefansson, S., & Lawrence, D. A. (1996) · Nature · doi:10.1038/383441a0 · Cited by 674
Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
Chapman, H. A. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80126-3 · Cited by 464
Montesano, R., Pepper, M. S., Möhle-Steinlein, U., Risau, W., Wagner, E. F., & Orci, L. (1990) · Cell · doi:10.1016/0092-8674(90)90009-4 · Cited by 454
Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., & Loskutoff, D. J. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.6.1563 · Cited by 448
Self-citationPlasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Bugge, T. H., Flick, M. J., Daugherty, C. C., & Degen, J. L. (1995) · Genes & Development · doi:10.1101/gad.9.7.794 · Cited by 438
Halting angiogenesis suppresses carcinoma cell invasion
Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., & Fusenig, N. E. (1997) · Nature Medicine · doi:10.1038/nm1197-1222 · Cited by 420
Self-citationCarmeliet, P., Stassen, J. M., Schoonjans, L., Ream, B., van den Oord, J. J., De Mol, M., Mulligan, R. C., & Collen, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116893 · Cited by 388
Self-citation
Cited by
Signaling Mechanisms Regulating Endothelial Permeability
Mehta, D., & Malik, A. B. (2006) · Physiological Reviews · doi:10.1152/physrev.00012.2005 · Cited by 1,720
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Self-citationCumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D'Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwm014 · Cited by 1,026
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
Clinical, Cellular, and Molecular Aspects of Cancer Invasion
Mareel, M., & Leroy, A. (2003) · Physiological Reviews · doi:10.1152/physrev.00024.2002 · Cited by 524
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Pericellular Proteases in Angiogenesis and Vasculogenesis
van Hinsbergh, V. W. M., Engelse, M. A., & Quax, P. H. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209518.58252.17 · Cited by 389
Bennett, R. E., Robbins, A. B., Hu, M., Cao, X., Betensky, R. A., Clark, T., Das, S., & Hyman, B. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710329115 · Cited by 299
Pleiotropic functions of plasminogen activator inhibitor-1
LIJNEN, H. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00827.x · Cited by 312
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
Devy, L., Blacher, S., Grignet-Debrus, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0552com · Cited by 280
Self-citationThe Adventitia: A Dynamic Interface Containing Resident Progenitor Cells
Majesky, M. W., Dong, X. R., Hoglund, V., Mahoney, W. M., & Daum, G. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.221549 · Cited by 267
Plasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis
McMahon, G. A., Petitclerc, E., Stefansson, S., Smith, E., Wong, M. K. K., Westrick, R. J., Ginsburg, D., Brooks, P. C., & Lawrence, D. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105980200 · Cited by 263
Molecular basis of endothelial cell morphogenesis in three‐dimensional extracellular matrices
Davis, G. E., Bayless, K. J., & Mavila, A. (2002) · The Anatomical Record · doi:10.1002/ar.10159 · Cited by 253
Metadata
- Authors
- Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., & Noël, A.
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2001-02-19
- Volume
- 152
- Issue
- 4
- Pages
- 777-784
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2137400219
- Cited by
- 314
- References
- 33
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.